Could a drug calm the immune storm in severe abdominal infections?
NCT ID NCT07672496
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether ulinastatin, a drug that reduces inflammation, can help patients with severe abdominal infections. The infection often causes the immune system to overreact, leading to organ failure and high risk of death. Researchers will give patients either a low or high dose of ulinastatin or a placebo for five days, alongside standard care, and measure changes in immune and inflammatory markers. The goal is to see if ulinastatin can restore immune balance and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ulinastatin
What this could lead to
If ulinastatin improves immune function and reduces inflammation, it could lead to a new treatment for severe abdominal infections and lower the risk of organ failure or death.
What could go wrong
This is a small, early pilot study, so results may not be conclusive. The drug may not show benefit, and there are always risks of side effects or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact